Investment Thesis
Anixa is a pre-revenue biotech company with critical financial distress: $210K revenue, -$5.4M operating losses, and only $1.5M cash against -$4.4M annual cash burn, implying <4 months runway. While balance sheet leverage is minimal and liquidity ratios are strong, the company faces imminent capital raise or insolvency without dramatic near-term revenue inflection that fundamentals do not suggest.
Strengths
- Excellent liquidity position with 9.79x current ratio provides near-term operational flexibility
- Minimal debt burden (0.03x debt-to-equity) reduces financial risk from leverage
- Improving loss trajectory: net loss and EPS both improved YoY, indicating cost control efforts
Risks
- Critical cash runway: $1.5M cash with $4.4M annual burn implies <4 months solvency at current rate
- Minimal revenue generation: $210K annual revenue with zero path to near-term profitability
- Unsustainable operating losses: -$5.4M operating loss on trivial revenue requires immediate dilutive capital raise or restructuring
- Negative cash flow from operations indicates fundamental business model is not generating value
Key Metrics to Watch
- Cash position and burn rate trajectory (survival metric)
- Revenue growth rate and new contract announcements
- Operating loss reduction and path to cash flow breakeven
Financial Metrics
Revenue
210.0K
Net Income
-5.1M
EPS (Diluted)
$-0.15
Free Cash Flow
-4.4M
Total Assets
14.9M
Cash
1.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,553.8%
Net Margin
-2,419.5%
ROE
-35.1%
ROA
-34.2%
FCF Margin
-2,079.4%
Balance Sheet & Liquidity
Current Ratio
9.79x
Quick Ratio
9.79x
Debt/Equity
0.03x
Debt/Assets
11.0%
Interest Coverage
-163.97x
Long-term Debt
370.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-06-11T07:20:58.216969 |
Data as of: 2026-04-30 |
Powered by Claude AI